Showing results (1-10 of 123) with videos related to
Sort By:
Pageof 13
Journal of Clinical Pharmacy and Therapeutics|April 1, 1996
G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluationA Messori, S Trippoli, E TendiCancer|December 1, 1996
Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. A lifetime cost-effectiveness analysisA Messori, S Trippoli, P Becagli, et al.Anti-Cancer Drugs|January 7, 1999
Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluationA Messori, S Trippoli, P Becagli, et al.European Journal of Cancer (Oxford, England : 1990)|August 1, 1997
A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanomaA Messori, P Becagli, S Trippoli, et al.European Journal of Clinical Pharmacology|January 1, 1996
Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancerA Messori, P Becagli, S Trippoli, et al.Oncology Reports|October 14, 1998
Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluationS Trippoli, A Messori, P Becagli, et al.Anti-Cancer Drugs|January 16, 1999
Pharmacoeconomic profile of taxanes in advanced ovarian cancerA Messori, S TrippoliOncology Reports|July 30, 1999
A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review)A Messori, S TrippoliComputer Programs in Biomedicine|February 1, 1984
A calculator program for least-squares parameter estimation according to the one-compartment kinetic model with zero-order inputA Messori, G Donati-Cori, E TendiJournal of Chemotherapy (Florence, Italy)|May 17, 2011
A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approachA Messori, V Fadda, S TrippoliPageof 13